ALS Treatment Extension Study

Inclusion Criteria: * Signed informed consent prior to initiation of any study-specific procedures and treatment * Documented completion of protocol-specific assessments following completion of six 28-day treatment cycles in study CMD-2016-001 * Principal Investigator considers the patient would benefit from continued treatment with Cu(II)ATSM * Not taking riluzole or on the same (or lower) dose used during the CMD-2016-001 study * Adequate bone marrow reserve, renal and liver function * Women and men with partners of childbearing potential must take effective contraception while on study treatment Exclusion Criteria: * Inability to swallow oral medications or presence of a gastrointestinal disorder (e.g.,malabsorption) deemed to jeopardize intestinal absorption of study drug * Dependence on mechanical ventilation (invasive or non-invasive) for any part of day or night, where dependence is defined as being unable to lie flat (supine) without it, unable to sleep without it, or daytime use * Dementia that may affect either outcome measures or patient understanding and/or compliance with study requirements and procedures * Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6